Soleno Therapeutics (SLNO) EBIT Margin (2016 - 2017)
Historic EBIT Margin for Soleno Therapeutics (SLNO) over the last 5 years, with Q2 2017 value amounting to 296800.0%.
- Soleno Therapeutics' EBIT Margin fell 1820500000.0% to 296800.0% in Q2 2017 from the same period last year, while for Dec 2017 it was 4575.56%, marking a year-over-year decrease of 35999300.0%. This contributed to the annual value of 81242.86% for FY2024, which is N/A changed from last year.
- Per Soleno Therapeutics' latest filing, its EBIT Margin stood at 296800.0% for Q2 2017, which was down 1820500000.0% from 518.11% recorded in Q1 2017.
- Over the past 5 years, Soleno Therapeutics' EBIT Margin peaked at 195.07% during Q2 2014, and registered a low of 296800.0% during Q2 2017.
- Over the past 5 years, Soleno Therapeutics' median EBIT Margin value was 645.95% (recorded in 2016), while the average stood at 28691.43%.
- As far as peak fluctuations go, Soleno Therapeutics' EBIT Margin surged by 100735800bps in 2016, and later tumbled by -1820500000bps in 2017.
- Quarter analysis of 5 years shows Soleno Therapeutics' EBIT Margin stood at 173.91% in 2013, then tumbled by -54bps to 79.54% in 2014, then crashed by -1926bps to 1452.24% in 2015, then skyrocketed by 56bps to 645.95% in 2016, then crashed by -45848bps to 296800.0% in 2017.
- Its last three reported values are 296800.0% in Q2 2017, 518.11% for Q1 2017, and 645.95% during Q4 2016.